Oral PCSK9 Inhibitor Shows Encouraging LDL LoweringA new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study.
The study was presented by Christie Ballantyne, MD, Baylor College of Medicine, Houston, Texas at the recent American College of Cardiology (ACC) Scientific Session/World Congress of Cardiology (WCC) 2023.
Cardiovascular Risk Factors Rife in Argentine CardiologistsDespite cardiologists' knowledge about cardiovascular disease and risk factors, they have a high prevalence of these risk factors. This observation suggests poor working conditions for cardiologists of both sexes and a high prevalence of workplace gender violence for female cardiologists, according to a study conducted by the Argentine Society of Cardiology (SAC).
New Tool Better Estimates Cardiovascular Risk in People With LupusA tool that incorporates lupus-related variables with traditional risk factors provides a much more accurate assessment of cardiovascular (CV) risk in patients with systemic lupus erythematosus (SLE), according to data presented at the annual meeting of the Canadian Rheumatology Association.
Dapagliflozin Gets Expanded Heart Failure Indication in EuropeThe European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum of left ventricular ejection fraction — including HF with mildly reduced and preserved ejection fraction, AstraZeneca has announced.
Cath Ablation for AF No Less Safe, Effective in Cancer PatientsCatheter ablation for atrial fibrillation (AF) is effective and safe in patients with a history of cancer and those receiving cardiotoxic therapies. The ablation success rate in patients with cancer was similar to that observed in patients without cancer.